The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amphion Innovations Agrees To Amend 2014 Loan Facility (ALLISS)

Mon, 11th Mar 2019 18:11

LONDON (Alliance News) - Amphion Innovations PLC said Monday it has amended its loan facility first agreed in 2014 and then amended last October.

Amphion amended the loan interest rate to 10% per annum and agreed to give the lender 15% of the appreciation on 10.0 million of Amphion's shares in Motif Bio PLC, above 33 pence. The 15% appreciation will be cut to 10% if the loan is fully repaid by the end of March.

Amphion and the lender have now agreed to sell USD750,00 of Motif Bio shares with two-thirds of the proceeds being used to reduce the loan balance, which currently stands at USD4.1 million.

Going forward, the loan interest rate will remain at 10% but the lender will receive 15% of the future appreciation of 10.0 million Motif shares above 10p and also 15% of the appreciation in 10.0 million Polarean Imaging PLC shares above 18p.

The agreement will end in September 2021 or when Amphion has sold all of its shares in Motif and Polarean.

Amphion's pledge of 24.5 million Motif shares will continue to act as Amphion's security for the loan. Amphion retains its beneficial interest in all pledged shares, although it has transferred the legal title to the majority of these.

Shares in Amphion Innovations closed flat Monday at 0.38 pence each.

More News
3 Jul 2018 10:47

Motif Bio Director Robert Bertoldi To Resign From Role July 16

LONDON (Alliance News) - Clinical-stage biopharmaceutical company Motif Bio PLC said Tuesday that Director Robert Bertoldi will resign from the board with effect on July 16.Chief Executive

Read more
23 May 2018 14:39

Amphion Sells 8.9 Million Shares In Motif Bio To Repay Loan Facility (ALLISS)

LONDON (Alliance News) - Amphion Innovations PLC said on Wednesday it sold 8.9 million shares in partner company Motif Bio PLC to partially repay a loan facility, as well as to fund ongoing &

Read more
17 May 2018 14:56

UPDATE: Motif Bio Completes GBP10 Million Fundraise Through Placing (ALLISS)

LONDON (Alliance News) - Biopharmaceutical firm Motif Bio PLC said it has successfully raised GBP10 million via an accelerated bookbuild exercise on Thursday.The company placed 32.3 million

Read more
17 May 2018 12:20

Motif Bio To Raise GBP10 Million Via Accelerated Share Bookbuild (ALLISS)

LONDON (Alliance News) - Motif Bio PLC said it plans to raise GBP10 million via an accelerated bookbuild exercise, which will launch on Thursday.The funds raised will be used by the company

Read more
19 Apr 2018 13:59

Motif Bio's Iclaprim Delivers Continued Good Test Results

LONDON (Alliance News) - Motif Bio PLC on Thursday said iclaprim delivered further positive results as part of its REVIVE-2 phase three trial.Motif Bio previously had said iclaprim showed a

Read more
20 Mar 2018 11:08

Motif Bio Delays Iclaprim New Drug Application, Shares Fall

LONDON (Alliance News) - Motif Bio PLC's shares fell on Tuesday as the biopharmaceutical company said it has pushed back the date for its new drug application submission a

Read more
7 Mar 2018 13:24

Motif Bio Issues 178,571 Shares Following Warrants Exercise (ALLISS)

LONDON (Alliance News) - Motif Bio PLC said Wednesday it has raised GBP57,499 through the issue of 178,571 shares at a price of 32.2 pence per of

Read more
31 Oct 2016 10:58

Motif Bio may need to raise cash as antibiotic trial accelerates

(ShareCast News) - As it prepares to list on the Nasdaq, AIM-listed antibiotics developer Motif Bio said it was likely to need extra funding as enrolments for its latest clinical trial were going faster than expected. Patient enrolment in Motif's Revive 1 phase-three trial has exceeded projections a

Read more
9 Aug 2016 09:43

WINNERS & LOSERS SUMMARY: Worldpay Bid Up After Strong First Half

Read more
13 Jul 2016 09:43

WINNERS & LOSERS SUMMARY: Poundland Jumps On Steinhoff Takeover Deal

Read more
13 Jul 2016 08:13

Motif Bio Shares Rise As It Files To List On NASDAQ Market (ALLIPO)

Read more
23 Jun 2016 09:01

Amphion Reports Huge Net Asset Value Rise Thanks To Motif Bio

Read more
28 Apr 2016 09:01

Amphion Innovations To Draw Debt To Repay Existing Borrowings

Read more
20 Apr 2016 07:31

Motif Bio Loss Widens In 2015 As It Continues Iclaprim Progression

Read more
14 Apr 2016 07:52

Motif Bio Appoints New Chief Financial Officer, Clinical Operations VP

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.